Regarding each disease outcome, among patients who initiated DPP-4 and SGLT2 inhibitors at hospitals with no history of that disease, the outcome event coverages in the same hospital were 49% (68/138) and 49% (29/59) for heart failure, 44% (34/78) and 55% (30/55) for stroke, and 38% (18/48) and 38% (14/37) for myocardial infarction, respectively. This evidence concerns the gene SLC5A2 and myocardial infarction.